241 related articles for article (PubMed ID: 34002394)
1. Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program.
Pernici CD; Mensah JA; Dahle EJ; Johnson KJ; Handy L; Buxton L; Smith MD; West PJ; Metcalf CS; Wilcox KS
Epilepsia; 2021 Jul; 62(7):1665-1676. PubMed ID: 34002394
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome.
Cao D; Ohtani H; Ogiwara I; Ohtani S; Takahashi Y; Yamakawa K; Inoue Y
Epilepsia; 2012 Jul; 53(7):1140-5. PubMed ID: 22578034
[TBL] [Abstract][Full Text] [Related]
3. Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.
Oakley JC; Cho AR; Cheah CS; Scheuer T; Catterall WA
J Pharmacol Exp Ther; 2013 May; 345(2):215-24. PubMed ID: 23424217
[TBL] [Abstract][Full Text] [Related]
4. Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study.
De Liso P; Chemaly N; Laschet J; Barnerias C; Hully M; Leunen D; Desguerre I; Chiron C; Dulac O; Nabbout R
Epilepsy Res; 2016 Sep; 125():42-6. PubMed ID: 27389706
[TBL] [Abstract][Full Text] [Related]
5. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome.
Alonso C; Satta V; Díez-Gutiérrez P; Fernández-Ruiz J; Sagredo O
Neuropharmacology; 2022 Mar; 205():108914. PubMed ID: 34875285
[TBL] [Abstract][Full Text] [Related]
6. A novel rat model of Dravet syndrome recapitulates clinical hallmarks.
Li M; Yang L; Qian W; Ray S; Lu Z; Liu T; Zou YY; Naumann RK; Wang H
Neurobiol Dis; 2023 Aug; 184():106193. PubMed ID: 37295561
[TBL] [Abstract][Full Text] [Related]
7. Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.
Hawkins NA; Zachwieja NJ; Miller AR; Anderson LL; Kearney JA
PLoS Genet; 2016 Oct; 12(10):e1006398. PubMed ID: 27768696
[TBL] [Abstract][Full Text] [Related]
8. Life-span characterization of epilepsy and comorbidities in Dravet syndrome mice carrying a targeted deletion of exon 1 of the Scn1a gene.
Gerbatin RR; Augusto J; Boutouil H; Reschke CR; Henshall DC
Exp Neurol; 2022 Aug; 354():114090. PubMed ID: 35487274
[TBL] [Abstract][Full Text] [Related]
9. Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in Dravet syndrome: a case report.
Horiuchi K; Kudo A; Nakamura S; Yamada K; Inoue T; Fujii S; Oshima Y
J Med Case Rep; 2024 Jan; 18(1):3. PubMed ID: 38167335
[TBL] [Abstract][Full Text] [Related]
10. Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome.
Anderson LL; Bahceci DA; Hawkins NA; Everett-Morgan D; Banister SD; Kearney JA; Arnold JC
PLoS One; 2023; 18(1):e0280842. PubMed ID: 36701411
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermia-Induced Seizures Enhance Brain Concentrations of the Endocannabinoid-Related Linoleoyl Glycerols in a
Bahceci D; Anderson LL; Kevin RC; Doohan PT; Arnold JC
Cannabis Cannabinoid Res; 2023 Jun; 8(3):495-504. PubMed ID: 36269656
[No Abstract] [Full Text] [Related]
12. Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation.
Ricobaraza A; Mora-Jimenez L; Puerta E; Sanchez-Carpintero R; Mingorance A; Artieda J; Nicolas MJ; Besne G; Bunuales M; Gonzalez-Aparicio M; Sola-Sevilla N; Valencia M; Hernandez-Alcoceba R
Sci Rep; 2019 Oct; 9(1):14172. PubMed ID: 31578435
[TBL] [Abstract][Full Text] [Related]
13. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
Aras LM; Isla J; Mingorance-Le Meur A
Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes.
Shi XY; Tomonoh Y; Wang WZ; Ishii A; Higurashi N; Kurahashi H; Kaneko S; Hirose S;
Brain Dev; 2016 Jan; 38(1):40-6. PubMed ID: 26183863
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABA
Nakakubo S; Hiramatsu Y; Goto T; Kimura S; Narugami M; Nakajima M; Ueda Y; Shiraishi H; Manabe A; Sharmin D; Cook JM; Egawa K
Front Pharmacol; 2023; 14():1273633. PubMed ID: 37849734
[No Abstract] [Full Text] [Related]
16. Proteomic signature of the Dravet syndrome in the genetic Scn1a-A1783V mouse model.
Miljanovic N; Hauck SM; van Dijk RM; Di Liberto V; Rezaei A; Potschka H
Neurobiol Dis; 2021 Sep; 157():105423. PubMed ID: 34144125
[TBL] [Abstract][Full Text] [Related]
17. Functional and structural deficits of the dentate gyrus network coincide with emerging spontaneous seizures in an Scn1a mutant Dravet Syndrome model during development.
Tsai MS; Lee ML; Chang CY; Fan HH; Yu IS; Chen YT; You JY; Chen CY; Chang FC; Hsiao JH; Khorkova O; Liou HH; Yanagawa Y; Lee LJ; Lin SW
Neurobiol Dis; 2015 May; 77():35-48. PubMed ID: 25725421
[TBL] [Abstract][Full Text] [Related]
18. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.
Hawkins NA; Jurado M; Thaxton TT; Duarte SE; Barse L; Tatsukawa T; Yamakawa K; Nishi T; Kondo S; Miyamoto M; Abrahams BS; During MJ; Kearney JA
Epilepsia; 2021 Nov; 62(11):2845-2857. PubMed ID: 34510432
[TBL] [Abstract][Full Text] [Related]
19. Audit of use of stiripentol in adults with Dravet syndrome.
Balestrini S; Sisodiya SM
Acta Neurol Scand; 2017 Jan; 135(1):73-79. PubMed ID: 27231140
[TBL] [Abstract][Full Text] [Related]
20. A 5-HT
Hatini PG; Commons KG
Eur J Neurosci; 2020 Nov; 52(10):4370-4374. PubMed ID: 32394465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
